Get the Stockscreener App
0.876
1.43%
-0.0127
After Hours:
.87
-0.006
-0.68%
Cosmos Health Inc stock is traded at $0.876, with a volume of 170.96K.
It is down -1.43% in the last 24 hours and down -24.81% over the past month.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
See More
Previous Close:
$0.8887
Open:
$0.8911
24h Volume:
170.96K
Relative Volume:
0.07
Market Cap:
$15.60M
Revenue:
$49.59M
Net Income/Loss:
$-15.61M
P/E Ratio:
-0.1529
EPS:
-5.7281
Net Cash Flow:
$-32.55M
1W Performance:
-13.27%
1M Performance:
-24.81%
6M Performance:
+23.38%
1Y Performance:
-44.20%
1-Day Range:
$0.8601
$0.9099
1-Week Range:
$0.8501
$1.07
52-Week Range:
$0.4677
$1.65
Cosmos Health Inc Stock (COSM) Company Profile
Name
Cosmos Health Inc
Sector
Industry
Phone
312-536-3102
Address
5 AGIOU GEORGIOU, PILEA, THESSALONIKI
Cosmos Health Inc Stock (COSM) Latest News
Cosmos Health (NASDAQ:COSM) vs. ScripsAmerica (OTCMKTS:SCRCQ) Critical Contrast - Defense World
Taking the lead: Cosmos Health Inc (COSM) - SETE News
Evaluating COSM’s financial ratios for a profitable investment - US Post News
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands - AccessWire
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands - StockTitan
Company’s Banking Shares: Up -50.73% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Investor’s Delight: Cosmos Health Inc (COSM) Closes Weak at 1.01, Down -8.18 - The Dwinnex
Cosmo First expects plastic business to turn profitable by the fourth quarter this year - CNBCTV18
Cosmos Health secures UK orders for antimicrobial wash By Investing.com - Investing.com Australia
Cosmos Health secures UK orders for antimicrobial wash By Investing.com - Investing.com Canada
Recovery room: Skye, Corbus mend post-Novo CB1 weight-loss data - BioWorld Online
Cosmos Health secures UK orders for antimicrobial wash - Investing.com
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins - Lelezard
Cosmos Health secures UK orders for antimicrobial wash - Investing.com India
Cosmos Health secures UK orders for antimicrobial wash - Investing.com UK
Financial Survey: ScripsAmerica (OTCMKTS:SCRCQ) versus Cosmos Health (NASDAQ:COSM) - Defense World
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins - AccessWire
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins - StockTitan
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits - Lelezard
Cosmos Health signs deal for mpox detection kits in India - Investing.com
Core Scientific (NASDAQ:CORZ) Coverage Initiated at Canaccord Genuity Group - Defense World
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits - AccessWire
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits - StockTitan
Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development - Newsfile
Cosmos Health begins development of new GI disorder treatment By Investing.com - Investing.com Australia
Railway stock hits 5% upper circuit after receiving order worth ₹ 127.4 Cr for steel sheet piles - Trade Brains
Here's why this multibagger railway wagon stock hit 5% upper circuit on September 20 - Moneycontrol
Cosmos Health begins development of new GI disorder treatment By Investing.com - Investing.com Canada
Cosmic CRF shares hit 5% upper circuit on Rs 127-crore order win; details - Business Standard
Cosmos Health begins development of new GI disorder treatment - Investing.com
Cosmos Health begins development of new GI disorder treatment By Investing.com - Investing.com UK
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion - Big News Network
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastroin - PharmiWeb.com
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion - AccessWire
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion - StockTitan
FY2024 EPS Estimates for Cosmos Health Inc. (NASDAQ:COSM) Reduced by Taglich Brothers - Defense World
Cosmos Health Inc. Expected to Earn Q1 2025 Earnings of ($0.07) Per Share (NASDAQ:COSM) - Defense World
Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments - AccessWire
Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments - StockTitan
Positive Ascendis data threatens BioMarin's lead in achondroplasia - The Pharma Letter
Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price - AccessWire
Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price - StockTitan
Cosmos Health to distribute mpox PCR kits across GCC, including Qatar - Doha News
Virax Biolabs expands Mpox test kit distribution in GCC By Investing.com - Investing.com Canada
Virax Biolabs expands Mpox test kit distribution in GCC - Investing.com
Cosmos Health expands mpox kit distribution to Gulf States - Investing.com
Cosmos Health expands mpox kit distribution to Gulf States - Investing.com India
Cosmos Health expands mpox kit distribution to Gulf States By Investing.com - Investing.com Canada
Cosmos Health expands mpox kit distribution to Gulf States By Investing.com - Investing.com UK
Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar - AccessWire
Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc. - StockTitan
Cosmos Health Inc Stock (COSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
9.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):